Atucha N M, Ortíz M C, Fortepiani L A, Ruiz F M, Martínez C, García-Estañ J
Departamento de Fisiologia, Facultad de Medicina, Universidad de Murcia, Spain.
Hepatology. 1998 Apr;27(4):900-5. doi: 10.1002/hep.510270402.
The mechanisms mediating the hyporesponsiveness to vasoconstrictors in portal hypertension are not completely established. In the present study, we evaluated the role of cyclic guanosine monophosphate (cGMP) and potassium channels as contributors to the pressor hyporesponsiveness to methoxamine (MTX) of the mesenteric vascular bed of portal vein-ligated (PVL) hypertensive rats. In basal conditions, and compared with sham-operated control rat (SHAM) vessels, PVL preparations showed a blunted pressor response (maximum: 39.3 +/- 6.1 vs. 94.5 +/- 8.9 mm Hg), which increased by pretreatment with methylene blue (MB), a guanylate cyclase inhibitor (118.7 +/- 8.9 vs. 152.0 +/- 10.0, respectively), and even more with the nitric oxide (NO) synthesis inhibitor N(omega)-nitro-L-arginine (NNA) (159.9 +/- 7.4 vs. 194.1 +/- 5.7, respectively), suggesting that NO acts through cGMP-dependent and independent mechanisms. In all cases, however, the pressor responses of PVL vessels were lower than those of SHAM. Pretreatment of the vessels with the potassium channel inhibitors, tetraethylammonium (TEA), glibenclamide (GLB), or charybdotoxin (CHX), did not improve the reduced pressor responses of the PVL rats. However, when the preparations were simultaneously pretreated with MB and TEA or with NNA and TEA, the pressor responses were potentiated with respect to groups treated with MB or NNA alone, and the differences between PVL and SHAM vessels were completely corrected. These data suggest that both NO and potassium channels mediate the vascular hyporesponsiveness to methoxamine of the PVL mesenteric vasculature. Our results also disclose that NO blunts the pressor response of the PVL vessels by a dual mechanism of action, through activation of potassium channels and through the formation of cGMP. Finally, the NO-independent component mediated by potassium channels can be only seen when the main cGMP-NO component is inactivated. In conclusion, both cGMP and potassium channels mediate the vascular hyporesponsiveness to MTX of the mesenteric bed of portal hypertensive rats.
门静脉高压时介导血管收缩剂反应性降低的机制尚未完全明确。在本研究中,我们评估了环磷酸鸟苷(cGMP)和钾通道在门静脉结扎(PVL)高血压大鼠肠系膜血管床对甲氧明(MTX)反应性降低中的作用。在基础状态下,与假手术对照大鼠(SHAM)的血管相比,PVL标本的升压反应减弱(最大值:39.3±6.1 vs. 94.5±8.9 mmHg),用鸟苷酸环化酶抑制剂亚甲蓝(MB)预处理后升压反应增强(分别为118.7±8.9 vs. 152.0±10.0),用一氧化氮(NO)合成抑制剂N(ω)-硝基-L-精氨酸(NNA)预处理后升压反应增强更明显(分别为159.9±7.4 vs. 194.1±5.7),提示NO通过cGMP依赖和非依赖机制发挥作用。然而,在所有情况下,PVL血管的升压反应均低于SHAM血管。用钾通道抑制剂四乙铵(TEA)、格列本脲(GLB)或蝎毒素(CHX)预处理血管,并未改善PVL大鼠减弱的升压反应。然而,当标本同时用MB和TEA或NNA和TEA预处理时,相对于单独用MB或NNA处理的组,升压反应增强,PVL和SHAM血管之间的差异完全得到纠正。这些数据表明,NO和钾通道均介导PVL肠系膜血管对甲氧明的血管反应性降低。我们的结果还揭示,NO通过激活钾通道和形成cGMP的双重作用机制减弱PVL血管的升压反应。最后,只有当主要的cGMP-NO成分失活时,由钾通道介导的NO非依赖成分才可见。总之,cGMP和钾通道均介导门静脉高压大鼠肠系膜床对MTX的血管反应性降低。